Lymphocytic Leukemia, Acute Clinical Trials
A listing of Lymphocytic Leukemia, Acute medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 79 clinical trials
Managed Access Program (MAP) to provide access to CTL019 for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …
- 0 views
- 19 Feb, 2024
- 1 location
A Pilot Study of Risk-Guided Cardioprotection with Carvedilol in Breast Cancer Patients Treated with Doxorubicin and/or Trastuzumab
If elevated risk, they will be randomized to intervention with carvedilol for 1 year vs usual care. Low risk subjects will be usual care. All subjects will be followed with serial echo, survey, and blood draws.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 21520: The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer
This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an effective method for treating cancer. All patients will receive binimetinib at a standard dose approved for other cancers. The dose of HCQ will also be fixed based on ongoing phase I studies.
- 0 views
- 19 Feb, 2024
- 1 location
A Pilot Study to Evaluate the Effect of CT1812 Treatment on A-beta Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease
Up to 18 subjects will be enrolled; interim analyses will be conducted after first 6 and next 6 to assess dosage of CT1812 and to determine if there is sufficient evidence of oligomer displacement to continue full trial with all 18 subjects.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 19418: A Phase 1/2a Dose-Finding Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma
The second part of the study involves treatment of an expansion cohort to confirm the tolerability of treatment at the recommended dose and evaluate evidence of treatment efficacy. All patients in the expansion cohort will be tested for genetic alterations in an effort to identify potential biomarkers for response to …
- 0 views
- 19 Feb, 2024
- 1 location
GENETICS MECHANISMS AND CLINICAL PHENOTYPES OF ARRHYTHMOGENIC CARDIOMYOPATHY
The well-established, consistent and precise phenotyping developed in the previous ARVC Registry (and published as the Modified Task Force Criteria), with a comprehensive primary genotyping approach, search for genetic modifiers, and biomarker analysis will fulfill the long-term goals of this proposal to identify the genetic basis of all forms of …
- 0 views
- 19 Feb, 2024
- 1 location
An Open-Label Phase 2 Proof or Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471
There will be a multi-step screening process. At the initial screening visit, all screening eligibility assessments, except the renal biopsy, will be performed. If the subject remains eligible based on the results from the initial screening visit, then arrangements can be made for renal biopsy and vaccinations.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 3 Randomized Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion (Cadenza)
For the purpose of marketing authorization application, an interim analysis of safety and efficacy data will be performed after all patients have completed the double-blind treatment period (Part A). The Part B open-label extension study will run for 1 year following last patient out (LPO) under Part A.
- 0 views
- 19 Feb, 2024
- 1 location
Towards predicting the analgesic response to ibuprofen following third-molar extraction
However, some patients experience only limited pain relief with ibuprofen, and a few experience no pain relief at all. These patients need a different type of pain reliever added to their regimen. The purpose of this study is to see if there are substances in your blood and urine which …
- 0 views
- 19 Feb, 2024
- 1 location